Gilead Sciences to Acquire Ouro Medicines for $2 Billion
Gilead Sciences is reportedly nearing a deal to acquire Ouro Medicines, an autoimmune biotech company, for up to $2 billion. This acquisition would expand Gilead's portfolio in the autoimmune disease space.